航天發展(000547.SZ):公司產品暫不涉及實戰應用
格隆匯5月21日丨航天發展(000547.SZ)在投資者互動平台表示,公司產品暫不涉及實戰應用。公司是一家以電子信息科技為主業,致力於軍用、民用產業領域的信息技術企業。公司根據“十四五”規劃中期調整方案,全面推進“藍軍體系及裝備、新一代通信與指控裝備、空間信息應用、數據智能與安全”等四個產業板塊發展,着力提升公司核心競爭力,更好地適應新質生產力、戰略性新興產業發展需要,進一步聚焦主責主業、堅定強軍首責、集聚優質資源,推動戰略目標落地,實現高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.